[
    [
        {
            "time": "",
            "orginal_text": "基因测序一周风云榜：药明康德市值蒸发超400亿元，达安基因“万绿丛中一点红” 连续下跌",
            "features": {
                "keywords": [
                    "药明康德",
                    "市值蒸发",
                    "连续下跌",
                    "达安基因"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "基因测序"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "基因测序一周风云榜：药明康德市值蒸发超400亿元，达安基因“万绿丛中一点红” 连续下跌",
            "scores": {
                "News_content": "基因测序一周风云榜：药明康德市值蒸发超400亿元，达安基因“万绿丛中一点红” 连续下跌",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "制药行业一周风云榜：CRO企业AH两市暴跌，药明康德市值一周缩水700亿 连续下跌",
            "features": {
                "keywords": [
                    "CRO",
                    "AH两市",
                    "暴跌",
                    "药明康德",
                    "市值缩水"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "制药行业一周风云榜：CRO企业AH两市暴跌，药明康德市值一周缩水700亿 连续下跌",
            "scores": {
                "News_content": "制药行业一周风云榜：CRO企业AH两市暴跌，药明康德市值一周缩水700亿 连续下跌",
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "昭衍新药港股上市，第四家“A+H”CRO企业诞生！",
            "features": {
                "keywords": [
                    "昭衍新药",
                    "港股上市",
                    "A+H",
                    "CRO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "昭衍新药港股上市，第四家“A+H”CRO企业诞生！",
            "scores": {
                "News_content": "昭衍新药港股上市，第四家“A+H”CRO企业诞生！",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "因可转换债券获转换 药明康德(02359)折让53.00%发行143.42万股H股",
            "features": {
                "keywords": [
                    "可转换债券",
                    "药明康德",
                    "折让",
                    "H股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "因可转换债券获转换 药明康德(02359)折让53.00%发行143.42万股H股",
            "scores": {
                "News_content": "因可转换债券获转换 药明康德(02359)折让53.00%发行143.42万股H股",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "行业专业分工明确，百洋将成继“药明康德”后又一专业第三方平台",
            "features": {
                "keywords": [
                    "百洋",
                    "药明康德",
                    "第三方平台"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "医疗平台"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "行业专业分工明确，百洋将成继“药明康德”后又一专业第三方平台",
            "scores": {
                "News_content": "行业专业分工明确，百洋将成继“药明康德”后又一专业第三方平台",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "【异动股】药明康德(02359-HK)跌3.12%",
            "features": {
                "keywords": [
                    "药明康德",
                    "异动股",
                    "下跌"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "【异动股】药明康德(02359-HK)跌3.12%",
            "scores": {
                "News_content": "【异动股】药明康德(02359-HK)跌3.12%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业2020年报及2021年一季报业绩前瞻：2020分化巨大 21Q1恢复良好",
            "features": {
                "keywords": [
                    "医药行业",
                    "2020年报",
                    "2021一季报",
                    "业绩前瞻",
                    "分化",
                    "恢复"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "医药行业2020年报及2021年一季报业绩前瞻：2020分化巨大 21Q1恢复良好",
            "scores": {
                "News_content": "医药行业2020年报及2021年一季报业绩前瞻：2020分化巨大 21Q1恢复良好",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "大摩：上调药明康德目标价至178港元，评级增持",
            "features": {
                "keywords": [
                    "大摩",
                    "药明康德",
                    "目标价",
                    "上调",
                    "增持"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "大摩：上调药明康德目标价至178港元，评级增持",
            "scores": {
                "News_content": "大摩：上调药明康德目标价至178港元，评级增持",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "新冠疗法临床试验中只有5%能够给出指导性结果？FDA代理局长联名发文",
            "features": {
                "keywords": [
                    "新冠疗法",
                    "临床试验",
                    "FDA",
                    "指导性结果"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "新冠治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "新冠疗法临床试验中只有5%能够给出指导性结果？FDA代理局长联名发文",
            "scores": {
                "News_content": "新冠疗法临床试验中只有5%能够给出指导性结果？FDA代理局长联名发文",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]